Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia.

There is conflicting information about the influence of body mass index (BMI) on the pharmacokinetics, toxicity, and outcome of chemotherapy. We compared pharmacokinetics, outcome, and toxicity data across 4 BMI groups (underweight, BMI < or = 10th percentile; normal; at risk of overweight, BMI > or = 85th and < 95th percentile; overweight, BMI > or = 95th percentile) in 621 children with acute lymphoblastic leukemia (ALL) treated on 4 consecutive St Jude Total Therapy studies. Chemotherapy doses were not adjusted to ideal BMI. Estimates of overall survival (86.1% +/- 3.4%, 86.0% +/- 1.7%, 85.9% +/- 4.3%, and 78.2% +/- 5.5%, respectively; P = .533), event-free survival (76.2% +/- 4.2%, 78.7% +/- 2.1%, 73.4% +/- 5.5%, and 72.7% +/- 5.9%, respectively; P = .722), and cumulative incidence of relapse (16.0% +/- 3.7%, 14.4% +/- 1.8%, 20.6% +/- 5.1%, and 16.7% +/- 5.1%, respectively; P = .862) did not differ across the 4 groups. In addition, the intracellular levels of thioguanine nucleotides and methotrexate polyglutamates did not differ between the 4 BMI groups (P = .73 and P = .74, respectively). The 4 groups also did not differ in the overall incidence of grade 3 or 4 toxicity during the induction or postinduction periods. Further, the systemic clearance of methotrexate, teniposide, etoposide, and cytarabine did not differ with BMI (P > .3). We conclude that BMI does not affect the outcome or toxicity of chemotherapy in this patient population with ALL.

[1]  J F Boisvieux,et al.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. , 1984, Drug metabolism reviews.

[2]  J. Reilly,et al.  No Evidence for an Effect of Nutritional Status at Diagnosis on Prognosis in Children with Acute Lymphoblastic Leukemia , 1998, Journal of pediatric hematology/oncology.

[3]  B. Horizonte,et al.  Malnutrition as a prognostic factor in lymphoblastic leukaemia: a multivariate analysis. , 1994, Archives of disease in childhood.

[4]  T. Robinson,et al.  Clinical practice. Overweight children and adolescents. , 2005, The New England journal of medicine.

[5]  D. Murry,et al.  Impact of nutrition on pharmacokinetics of anti‐neoplastic agents , 1998, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[6]  David W. Henry,et al.  Obesity in pediatric oncology , 2005, Pediatric blood & cancer.

[7]  M. Relling,et al.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. , 1998, The New England journal of medicine.

[8]  Ching-Hon Pui,et al.  Limited and Optimal Sampling Strategies for Etoposide and Etoposide Catechol in Children with Leukemia , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[9]  B. Bochner,et al.  Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? , 2004, The Journal of urology.

[10]  G. Hortobagyi,et al.  Obesity as an Adverse Prognostic Factor for Patients Receiving Adjuvant Chemotherapy for Breast Cancer , 1994, Annals of Internal Medicine.

[11]  M. Vignetti,et al.  Obesity and autologous stem cell transplantation in acute myeloid leukemia , 2001, Bone Marrow Transplantation.

[12]  K. Flegal,et al.  Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. , 2004, JAMA.

[13]  J. Stockman.  Mortality in Overweight and Underweight Children with Acute Myeloid Leukemia , 2006 .

[14]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.

[15]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[16]  Lester R Curtin,et al.  Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. , 2002, Pediatrics.

[17]  Thomas N. Robinson,et al.  Overweight Children and Adolescents , 2005 .

[18]  S. Steinberg,et al.  Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. , 1995, Journal of the National Cancer Institute.

[19]  S. Guandalini,et al.  Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. , 1991, Therapeutic drug monitoring.

[20]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[21]  G. Ruiz-Argüelles,et al.  Leukaemia and nutrition. I: Malnutrition is an adverse prognostic factor in the outcome of treatment of patients with standard-risk acute lymphoblastic leukaemia. , 1989, Leukemia research.

[22]  E. Cook,et al.  Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Gelber,et al.  Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index , 2005, The Lancet.

[24]  G. Ruiz-Argüelles,et al.  Nutritional status and socio‐economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia , 1998, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[25]  M. Relling,et al.  Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. , 1999, Blood.

[26]  Hans C. Jessen,et al.  Applied Logistic Regression Analysis , 1996 .

[27]  D.,et al.  Regression Models and Life-Tables , 2022 .

[28]  A. Bleyer,et al.  Obesity and Body Weight Independently Predict Relapse and Survival in Preadolescents and Teenagers with Acute Lymphoblastic Leukemia (ALL). A Retrospective Analysis of Five Children Cancer Group (CCG) Studies. , 2004 .

[29]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[30]  U. Ligges.  Review of An R and S-PLUS companion to applied regression by J. Fox, Sage Publications, Thousand Oaks, California 2002 , 2003 .

[31]  J. Ingle,et al.  Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients , 2004, Cancer Chemotherapy and Pharmacology.

[32]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[33]  D. Wypij,et al.  Impact of body composition on pharmacokinetics of doxorubicin in pediatric patients: A Glaser Pediatric Research Network study , 2005 .

[34]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[35]  W J Jusko,et al.  Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity , 1991, Clinical pharmacology and therapeutics.

[36]  F. Behm,et al.  Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. , 1998, Blood.

[37]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[38]  M. Relling,et al.  Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia , 2000, Leukemia.

[39]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[40]  A. Goldhirsch,et al.  Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  J. Meyerhardt,et al.  Influence of body mass index on outcomes and treatment‐related toxicity in patients with colon carcinoma , 2003, Cancer.